← Back to Search

NMDA Receptor Antagonist

Low Ketamine, TS-134 for Healthy Subjects

Phase 1
Waitlist Available
Led By Joshua Kantrowitz, MD
Research Sponsored by New York State Psychiatric Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and day 4
Awards & highlights

Summary

This trialwill test the effectiveness of ketamine & a drug called TS-134 to treat depression in 120 people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and day 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and day 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Brief Psychiatric Rating Scale (BPRS)
Final PharmacoBOLD signals in pre-specified ROIs

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: Medium Ketamine, TS-134Experimental Treatment2 Interventions
Two administrations of ketamine 0.125 mg/kg pre post 4 days of TS-134 20 mg
Group II: Low Ketamine, TS-134Experimental Treatment2 Interventions
Two administrations of ketamine 0.06 mg/kg pre post 4 days of TS-134 20 mg
Group III: High Ketamine, TS-134Experimental Treatment2 Interventions
Two administrations of ketamine 0.23 mg/kg pre post 4 days of TS-134 20 mg
Group IV: Low Ketamine, placeboPlacebo Group2 Interventions
Two administrations of ketamine 0.06 mg/kg pre post 4 days of placebo
Group V: High ketamine, placeboPlacebo Group2 Interventions
Two administrations of ketamine 0.23 mg/kg pre post 4 days of placebo
Group VI: Medium Ketamine, placeboPlacebo Group2 Interventions
Two administrations of ketamine 0.125 mg/kg pre post 4 days of placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
2011
Completed Phase 4
~1120

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

New York State Psychiatric InstituteLead Sponsor
475 Previous Clinical Trials
153,535 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,820 Previous Clinical Trials
2,692,699 Total Patients Enrolled
Joshua Kantrowitz, MDPrincipal InvestigatorNYSPI
1 Previous Clinical Trials
24 Total Patients Enrolled
~42 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top